Clinical Trials Logo

Hyperoxaluria, Primary clinical trials

View clinical trials related to Hyperoxaluria, Primary.

Filter by:

NCT ID: NCT04555486 Completed - Clinical trials for Primary Hyperoxaluria Type 3

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

PHYOX4
Start date: September 14, 2020
Phase: Phase 1
Study type: Interventional

The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.

NCT ID: NCT04542590 Active, not recruiting - Clinical trials for Primary Hyperoxaluria Type 3

Natural History of Patients With PH3 and a History of Stone Events

PHYOX-OBX
Start date: September 9, 2021
Phase:
Study type: Observational [Patient Registry]

This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.

NCT ID: NCT04152200 Active, not recruiting - Clinical trials for Primary Hyperoxaluria

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

ILLUMINATE-C
Start date: January 21, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).

NCT ID: NCT04125472 Approved for marketing - Clinical trials for Primary Hyperoxaluria

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide expanded access to lumasiran for adults and pediatric patients with Primary Hyperoxaluria Type 1 (PH1),

NCT ID: NCT04042402 Enrolling by invitation - Kidney Diseases Clinical Trials

Long Term Extension Study in Patients With Primary Hyperoxaluria

PHYOX3
Start date: July 9, 2019
Phase: Phase 3
Study type: Interventional

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.

NCT ID: NCT03938272 Terminated - Clinical trials for Hyperoxaluria, Primary

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

ePHex-OLE
Start date: March 14, 2019
Phase: Phase 3
Study type: Interventional

Open label extension study of Oxabact OC5 in patients with primary hyperoxaluria

NCT ID: NCT03905694 Active, not recruiting - Clinical trials for Primary Hyperoxaluria

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

ILLUMINATE-B
Start date: April 22, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).

NCT ID: NCT03847909 Completed - Kidney Diseases Clinical Trials

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

PHYOX2
Start date: October 28, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)

NCT ID: NCT03819647 Completed - Clinical trials for Primary Hyperoxaluria

Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria

Start date: May 21, 2019
Phase: Phase 2
Study type: Interventional

Evaluation of the efficacy of stiripentol (Diacomit) as monotherapy for the treatment of primary hyperoxaluria. Pilot clinical study, open, prospective and multicenter.

NCT ID: NCT03681184 Completed - Clinical trials for Primary Hyperoxaluria Type 1 (PH1)

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

ILLUMINATE-A
Start date: November 27, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).